Skip to main content



) --



shares fell almost 5% Friday after its cancer drug iniparib didn't meet primary endpoints of overall survival and progression-free survival for breast cancer patients.

The Phase III clinical trial evaluated in patients with metastatic triple-negative breast cancer. The study enrolled 519 women with the cancer from 109 sites in the United States. Patients were randomized to receive a standard chemotherapy regimen (gemcitabine and carboplatin) with iniparib to one without the drug.

Scroll to Continue

TheStreet Recommends

Sanofi-Aventis, the French drugmaker, said there wasn't a significant difference between the two regimens.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here:

Joseph Woelfel

>To submit a news tip, send an email to:


Copyright 2011 Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. AP contributed to this report.